We are live on ! Find out more
PKBO

Peak Bio, Inc. Common Stock
PKBO

Delisted

PKBO was delisted on the 9th of January, 2023.

Back to rankings

24 hedge funds and large institutions have $21.9M invested in Peak Bio, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 7 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

900% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 1

60% more funds holding

Funds holding: 15 → 24 (+9)

49% more capital invested

Capital invested by funds: $14.7M → $21.9M (+$7.24M)

4.64% more ownership

Funds ownership: 26.39% → 31.03% (+4.6%)

Holders
24
Holders Change
+9
Holders Change %
+60%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
7
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
KPF
K2 Principal Fund
Ontario, Canada
+$1.96M
2
DKCM
Davidson Kempner Capital Management
New York
+$1.72M
3
BFM
Boothbay Fund Management
New York
+$986K
4
SCM
Saba Capital Management
New York
+$707K
5
CM
Cohanzick Management
New York
+$491K

Top Sellers

Rank Fund Capital Flow
1
LA
Linden Advisors
New York
-$1.18M

PKBO Hedge Fund Activity: Q2 2021 in Review

24 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Peak Bio, Inc. Common Stock (PKBO) for Q2 2021, worth a combined $21.9M — up 49% from $14.7M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new PKBO positions and 1 closed out — a net gain of 9 holders — while 7 added to existing stakes and 0 trimmed.

The largest buyer was K2 Principal Fund, adding an estimated $1.96M. The largest seller was Linden Advisors, exiting entirely with an estimated $1.18M sold.

  • 24 institutional investors held Peak Bio, Inc. Common Stock (PKBO) as of Q2 2021, up from 15 in Q1 2021.
  • Funds reported $21.9M of Peak Bio, Inc. Common Stock stock for Q2 2021, up 49% quarter-over-quarter.
  • 10 funds opened new Peak Bio, Inc. Common Stock positions in Q2 2021 and 1 closed out, a net change of +9 holders.
  • The largest Peak Bio, Inc. Common Stock buyer in Q2 2021 was K2 Principal Fund, an estimated $1.96M added.
  • The largest Peak Bio, Inc. Common Stock seller in Q2 2021 was Linden Advisors, an estimated $1.18M sold.

Based on aggregated 13F filings for Q2 2021.